Cutler Group’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q2
Sell
-2,500
Closed -$6K 4939
2018
Q1
$6K Sell
2,500
-5,500
-69% -$34K ﹤0.01% 3199
2017
Q4
$24K Sell
8,000
-51,000
-86% -$379K ﹤0.01% 2415
2017
Q3
$71K Sell
59,000
-5,900
-9% -$48K ﹤0.01% 1940
2017
Q2
$146K Buy
64,900
+55,800
+613% +$455K 0.01% 1543
2017
Q1
$11K Buy
9,100
+3,900
+75% +$31.9K ﹤0.01% 3960
2016
Q4
$8K Sell
5,200
-8,600
-62% -$64.3K ﹤0.01% 4491
2016
Q3
$5K Sell
13,800
-3,700
-21% -$20.9K ﹤0.01% 4997
2016
Q2
$13K Buy
17,500
+14,500
+483% +$77.7K ﹤0.01% 3868
2016
Q1
$1K Buy
+3,000
New +$17.7K ﹤0.01% 6159

Other funds holding VCYT

Cutler Group's VCYT Position: Q2 2021 in Review

Cutler Group sold out of Veracyte (VCYT) in Q2 2021, closing a stake of 400 shares — an estimated $21K sold.

Cutler Group first reported a position in VCYT in Q2 2016 and held it in 9 quarters. The position peaked at $454K in Q2 2017. 214 funds tracked by Wall St. Rank hold VCYT as of Q2 2021.

  • Cutler Group reported no remaining Veracyte position as of Q2 2021 after selling out during the quarter.
  • Cutler Group sold 400 Veracyte shares in Q2 2021, an estimated $21K.
  • Cutler Group first reported a position in Veracyte in Q2 2016 and held it in 9 quarters.
  • Cutler Group's Veracyte position peaked at $454K in Q2 2017.
  • 214 funds tracked by Wall St. Rank held Veracyte as of Q2 2021.

Based on Cutler Group's 13F filing for Q2 2021, filed 19 Jul 2021.